Department of Pathology, MLN Medical College, Allahabad, India.
J Biomed Sci. 2010 Feb 15;17(1):10. doi: 10.1186/1423-0127-17-10.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that are capable of cleaving all extra cellular matrix (ECM) substrates. Degradation of matrix is a key event in progression, invasion and metastasis of potentially malignant and malignant lesions of the head and neck. It might have an important polymorphic association at the promoter regions of several MMPs such as MMP-1 (-1607 1G/2G), MMP-2 (-1306 C/T), MMP-3 (-1171 5A/6A), MMP-9 (-1562 C/T) and TIMP-2 (-418 G/C or C/C). Tissue inhibitors of metalloproteinases (TIMPs) are naturally occurring inhibitors of MMPs, which inhibit the activity of MMPs and control the breakdown of ECM. Currently, many MMP inhibitors (MMPIs) are under development for treating different malignancies. Useful markers associated with molecular aggressiveness might have a role in prognostication of malignancies and to better recognize patient groups that need more antagonistic treatment options. Furthermore, the introduction of novel prognostic markers may also promote exclusively new treatment possibilities, and there is an obvious need to identify markers that could be used as selection criteria for novel therapies. The objective of this review is to discuss the molecular functions and polymorphic association of MMPs and TIMPs and the possible therapeutic aspects of these proteinases in potentially malignant and malignant head and neck lesions. So far, no promising drug target therapy has been developed for MMPs in the lesions of this region. In conclusion, further research is required for the development of their potential diagnostic and therapeutic possibilities.
基质金属蛋白酶（MMPs）是一类锌依赖性蛋白酶，能够切割所有细胞外基质（ECM）底物。基质的降解是头颈部潜在恶性和恶性病变进展、侵袭和转移的关键事件。它可能在几种 MMP 的启动子区域具有重要的多态性关联，例如 MMP-1（-1607 1G/2G）、MMP-2（-1306 C/T）、MMP-3（-1171 5A/6A）、MMP-9（-1562 C/T）和 TIMP-2（-418 G/C 或 C/C）。金属蛋白酶组织抑制剂（TIMPs）是 MMPs 的天然抑制剂，可抑制 MMP 的活性并控制 ECM 的分解。目前，许多 MMP 抑制剂（MMPI）正在开发中，用于治疗不同的恶性肿瘤。与分子侵袭性相关的有用标志物可能在恶性肿瘤的预后中发挥作用，并更好地识别需要更多拮抗治疗选择的患者群体。此外，新型预后标志物的引入也可能促进新的治疗可能性，因此显然需要确定可作为新型治疗选择的标志物。本综述的目的是讨论 MMPs 和 TIMPs 的分子功能和多态性关联，以及这些蛋白酶在头颈部潜在恶性和恶性病变中的可能治疗方面。迄今为止，尚未对头颈部区域的这些病变开发出有前途的药物靶点治疗方法。总之，需要进一步研究以开发其潜在的诊断和治疗可能性。
